SDMHF - Sartorius acquires cell culture specialist Xell AG

The life science company Sartorius (OTCPK:SARTF), through its subgroup Sartorius Stedim Biotech (OTCPK:SDMHF), acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany. Xell AG develops, produces, and markets media and feed supplements for cell cultures, especially for manufacturing viral vectors used in gene therapeutics and vaccines. Xell AG also offers various analytical services for characterizing, screening and quantifying media components. The purchase price is ~50 million euros in addition to two earn–out components contingent upon the achievement of defined revenue targets from 2022 to 2025. Xell AG is expected to generate sales revenue of ~5 million euros, and a substantial two-digit EBITDA margin for the full year of 2021. "With this acquisition, we are expanding our current media offering specifically by specialized media for manufacturing viral vectors and, additionally, in the area of media analytics..".

For further details see:

Sartorius acquires cell culture specialist Xell AG